Refinement of the MHC risk map in a scandinavian primary sclerosing cholangitis population

PLoS One. 2014 Dec 18;9(12):e114486. doi: 10.1371/journal.pone.0114486. eCollection 2014.

Abstract

Background: Genetic variants within the major histocompatibility complex (MHC) represent the strongest genetic susceptibility factors for primary sclerosing cholangitis (PSC). Identifying the causal variants within this genetic complex represents a major challenge due to strong linkage disequilibrium and an overall high physical density of candidate variants. We aimed to refine the MHC association in a geographically restricted PSC patient panel.

Methodology/principal findings: A total of 365 PSC cases and 368 healthy controls of Scandinavian ancestry were included in the study. We incorporated data from HLA typing (HLA-A, -B, -C, -DRB3, -DRB1, -DQB1) and single nucleotide polymorphisms across the MHC (n = 18,644; genotyped and imputed) alongside previously suggested PSC risk determinants in the MHC, i.e. amino acid variation of DRβ, a MICA microsatellite polymorphism and HLA-C and HLA-B according to their ligand properties for killer immunoglobulin-like receptors. Breakdowns of the association signal by unconditional and conditional logistic regression analyses demarcated multiple PSC associated MHC haplotypes, and for eight of these classical HLA class I and II alleles represented the strongest association. A novel independent risk locus was detected near NOTCH4 in the HLA class III region, tagged by rs116212904 (odds ratio [95% confidence interval] = 2.32 [1.80, 3.00], P = 1.35×10-11).

Conclusions/significance: Our study shows that classical HLA class I and II alleles, predominantly at HLA-B and HLA-DRB1, are the main risk factors for PSC in the MHC. In addition, the present assessments demonstrated for the first time an association near NOTCH4 in the HLA class III region.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Case-Control Studies
  • Cholangitis, Sclerosing / genetics*
  • HLA-B Antigens / genetics*
  • HLA-DRB1 Chains / genetics*
  • Humans
  • Polymorphism, Single Nucleotide*
  • Proto-Oncogene Proteins / genetics
  • Receptor, Notch4
  • Receptors, Notch / genetics
  • Scandinavian and Nordic Countries

Substances

  • HLA-B Antigens
  • HLA-DRB1 Chains
  • NOTCH4 protein, human
  • Proto-Oncogene Proteins
  • Receptor, Notch4
  • Receptors, Notch

Grants and funding

The study received support from the Norwegian PSC research center, the Research Computing Services at the University of Oslo and the DFG Excellence Cluster "Inflammation at Interfaces". Grant support was also received from the EU Seventh Framework Programme (FP7/2007-2013, grant number 262055, ESGI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.